Achievements of UZH Spin-offs

UZH Spin-offs are impressive both in their development and their success – the latest news is outlined below:

Foto Wyss Zurich

15.01.2026 | Bio-engineered skin grafts can play an important role in the treatment of burn victims. Researchers at UZH have been working on new approaches for such grafts for over 15 years. This work led to the creation of Cutiss in 2017, a spin-off that produces living skin tissue from the patients’ own cells. 

UZH article "New Skin for Burn Victims"

CUTISS Team

22.09.2025 | The UZH Spin-off has successfully raised 56 CHF million in a Series C financing round. This investment will support the ongoing Phase 3 studies on denovoSkin™ and prepare for its market launch.

CUTISS announcement
Entire news story
 

08.09.2025 | Since 2011 the TOP 100 Swiss Startup Ranking has been selecting the most promising young companies in Switzerland. The 2025 ranking shows the UZH's outstanding role as a nurturing group for innovative life sciences startups. Special Congratulations to MUVON that makes it Top 3 in BioTech and to the Newcomers MetaLead and Nerai Biosciences!

Entire news story
TOP 100 Swiss Startup Ranking

Dario Dornbirer, Co-Founder

22.08.2025 | The UZH Spin-off has successfully emerged from stealth mode and is on track to bring its groundbreaking therapies for neuropsychiatric disorders to patients. Through novel, specifically developed pharmacological agents, they are developing therapies for neuropsychiatric disorders such as PTSD, anxiety disorders, insomnia, and addiction. 

Entire news story

askEarth Team

25.07.2025 | With an intuitive search engine for satellite data, the UZH Spin-off is putting Earth observation at the fingertips of the public – and has now received CHF 2.26 million to scale up its operations. askEarth was founded in 2022 as a UZH spin-off. Co-founder and CTO Simon Grüning was awarded a UZH Entrepreneur Fellowship in 2022. 

Entire news story
Entrepreneurship Fellow Profile Simon Grüning

Michal Shoshan

22.08.2025 | The UZH Spin-off announces a CHF 1 million funding from the UZH Life Sciences Fund. metaLead is developing a new class of metal-binding drugs aimed at overcoming the shortcomings of existing chelation therapies. Michal Soshan was awarded a UZH Entrepreneur Fellowship in 2023. 

Entire news story
Entrpreneur Fellow Profile Michal Shoshan